Our NAV-005 antagonist binds the immunosuppressive HIO-1 factor and blocks its ability to suppress mAb, TCE and ADC ...
This new article publication from Acta Pharmaceutica Sinica B, discusses the construction of a localized immune niche via supramolecular hydrogel vaccine to elicit durable and enhanced immunity ...
Century Therapeutics (IPSC) aims at a durable “once-and-done” Type 1 diabetes cure with hypoimmune iPSC beta cells; runway to ...
CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...
The in situ formed hydrogel vaccine creates an immune niche to coordinate the spatiotemporal dynamics of vaccine components and dendritic cells, eliciting durable and enhanced immunity against ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results